ドラベ症候群の世界市場

ドラベ症候群の世界市場は2030年までに4億2,540万米ドルに達する見込み

2024年に2億6,390万米ドルと推定されるドラベ症候群の世界市場は、分析期間2024～2030年にCAGR 8.3％で成長し、2030年には4億2,540万米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるミオクロニー発作は、CAGR 10.3%を記録し、分析期間終了時には1億3,050万米ドルに達すると予測されます。無緊張発作分野の成長率は、分析期間中CAGR 5.7%と推定されます。

米国市場は7,190万米ドルと推定、中国はCAGR13.2％で成長予測

米国のドラベ症候群市場は、2024年に7,190万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGR13.2%で推移し、2030年には予測市場規模9,330万米ドルに達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ4.0％と8.0％と予測されています。欧州では、ドイツがCAGR 5.5%で成長すると予測されています。

世界の「ドラベ症候群」市場- 主要動向と促進要因のまとめ

ドラベ症候群が世界のヘルスケア市場で注目を集める理由とは？

ドラベ症候群は、乳幼児期に発症する希少かつ重篤なてんかんであり、その複雑な治療課題と発症意識の高まりから、現在、世界のヘルスケアコミュニティから高い注目を集めています。歴史的に過小診断され、誤解されてきたが、最近の遺伝子スクリーニングの進歩（特にSCN1A変異）により、診断精度が大幅に向上し、より早期かつ正確な発見が可能となりました。世界中でおよそ15,000人から21,000人に1人の割合で乳児が罹患するとされるこの疾患は、神経発達とQOLに多大な影響を及ぼすことから、小児神経学研究の最前線に位置づけられています。アドボカシー団体やデジタル啓発キャンペーンによって希少疾患の認知度が高まったことで、製薬会社や規制当局も研究、治療承認、同情的使用プログラムの迅速化を後押ししています。北米、欧州、そしてアジア太平洋の医療機関は、Dravetのような希少症候群に特化したてんかん専門センターを設立し、神経科医、遺伝専門医、発達専門医を含む包括的な治療を促進しています。このような世界の機運は、研究助成のあり方を変え、より効果的な管理に向けて、複数の利害関係者が協力するアプローチを促進しつつあります。

治療法の進歩は治療状況をどのように変えているのか？

ドラベ症候群の治療法は近年大きく進化し、従来の抗てんかん薬（AED）にとどまらず、標的治療薬や新規治療薬も含まれるようになりました。バルプロ酸塩やクロバザムのような従来のAEDは依然として基本的な治療薬であるが、発作の抑制には限界があることが多く、より専門的な薬剤開発における技術革新が急増しています。FDAが承認したカンナビジオール（CBD）ベースのエピディオレックスやフェンフルラミン（フィンテプラ）などの治療薬は、Dravet患者の発作頻度や重症度の減少において顕著な改善を示しています。さらに、ほとんどのDravet症例の根本原因であるナトリウムチャネル機能障害を標的とした治験中の治療薬もあり、臨床試験のさまざまな段階にあります。アンチセンスオリゴヌクレオチド（ASO）、遺伝子治療アプローチ、RNA標的薬などが、対症療法ではなく疾患修飾の可能性を持つ有望な候補として浮上しています。これらの治療法は、個々の患者に合わせてレジメンを調整するために、デジタルモニタリングツールや薬理遺伝学的検査と組み合わされることが多くなってきています。治療法の進化は、臨床転帰を改善するだけでなく、患者の安全性を高め、介護者の負担を軽減し、長期的な神経発達上の利益への扉を開いています。

なぜ患者擁護と規制上のインセンティブがイノベーションを加速しているのか？

患者擁護団体の影響力の増大と希少疾患への資金提供のエコシステムの拡大は、ドラベ症候群市場における主要な促進要因です。ドラベ症候群財団や欧州の関連団体のような組織は、家族、臨床医、研究者を結びつけ、認知、教育、共同研究を推進する上で重要な役割を果たしています。彼らの努力は、治療プロトコルを改良するのに不可欠な臨床試験への参加や実データ収集の増加につながりました。規制面では、FDA、EMA、PMDAなどの機関が希少小児疾患や希少疾病用医薬品の指定を導入し、市場独占権、税制優遇措置、迅速承認などをドラベ関連の治療法の開発者に与えています。これらの優遇措置は、バイオテクノロジー企業の参入障壁を大幅に引き下げ、有望な科学を利用可能な治療法に転換するために必要な、小規模な臨床試験であっても注目されることを保証するものです。製薬企業も希少疾病用医薬品の商業的可能性を認識しており、神経発達障害分野におけるライセンシング契約の増加、研究開発投資の増加、ポートフォリオの拡充につながっています。

ドラベ症候群市場の成長はいくつかの要因によってもたらされる...

ドラベ症候群市場の成長は、技術的ブレークスルー、進化するエンドユーザーニーズ、政策枠組みの変化に関連するいくつかの要因によって牽引されています。遺伝子検査と次世代シーケンシングの進歩により、診断率が大幅に向上し、早期介入と精密医療の可能性が可能になりました。治療面では、特にFDAやEMAの承認を得た新薬の登場により、臨床経路が変化し、治療の選択肢が広がりました。最終用途の観点からは、小児神経センター、希少疾患クリニック、統合ケアモデルなどが集学的アプローチを採用し、専門的な診断薬や医薬品に対する安定した需要を生み出しています。消費者の行動、特に情報通で積極的な介護者の間では、よりオーダーメイドで最先端の治療レジメンが求められており、イノベーションへの需要が高まっています。さらに、政府の支援政策、希少疾患登録、官民の研究協力が、継続的な医薬品開発と市場開拓のための肥沃な土壌を形成しています。このようなダイナミクスが相まって、かつては十分な治療が受けられない疾患であったものが、大きなアンメットニーズと長期的な成長の可能性を秘めた、急速に発展しつつあるニッチ市場へと変貌しつつあります。

セグメント

発作タイプ（ミオクロニー発作、アトニック発作、部分発作、強直間代発作、光過敏性発作、その他の発作タイプ）、診断タイプ（磁気共鳴画像診断、心電図診断、SCN1A検査診断）、治療タイプ（薬物治療、ケトジェニック・ダイエット治療、迷走神経刺激治療）、エンドユーザー（製薬企業エンドユーザー、病院エンドユーザー、診断研究所エンドユーザー、その他のエンドユーザー）

調査対象企業の例（注目の44社）

• Anavex Life Sciences Corp.
• Aquestive Therapeutics, Inc.
• Biocodex S.A.
• Biscayne Neurotherapeutics, Inc.
• Eisai Co., Ltd.
• Encoded Therapeutics
• Epygenix Therapeutics, Inc.
• GW Pharmaceuticals plc
• INSYS Therapeutics, Inc.
• Marinus Pharmaceuticals, Inc.
• Neurocrine Biosciences, Inc.
• OPKO Health Inc.
• Otsuka Holdings Co., Ltd.
• Ovid Therapeutics Inc.
• PTC Therapeutics, Inc.
• Sage Therapeutics, Inc.
• Stoke Therapeutics, Inc.
• Supernus Pharmaceuticals, Inc.
• Takeda Pharmaceutical Company Ltd.
• Xenon Pharmaceuticals Inc.

AIインテグレーション

私たちは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Dravet Syndrome Market to Reach US$425.4 Million by 2030

The global market for Dravet Syndrome estimated at US$263.9 Million in the year 2024, is expected to reach US$425.4 Million by 2030, growing at a CAGR of 8.3% over the analysis period 2024-2030. Myoclonic Seizures, one of the segments analyzed in the report, is expected to record a 10.3% CAGR and reach US$130.5 Million by the end of the analysis period. Growth in the Atonic Seizures segment is estimated at 5.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$71.9 Million While China is Forecast to Grow at 13.2% CAGR

The Dravet Syndrome market in the U.S. is estimated at US$71.9 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$93.3 Million by the year 2030 trailing a CAGR of 13.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.0% and 8.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.5% CAGR.

Global "Dravet Syndrome" Market - Key Trends & Drivers Summarized

Why Is Dravet Syndrome Garnering More Attention in the Global Healthcare Landscape?

Dravet Syndrome, a rare and severe form of epilepsy that begins in infancy, is now receiving heightened attention from the global healthcare community due to its complex treatment challenges and rising incidence awareness. Historically underdiagnosed and misunderstood, recent advancements in genetic screening-particularly for SCN1A mutations-have greatly improved diagnostic precision, enabling earlier and more accurate detection. With approximately 1 in 15,000 to 1 in 21,000 infants affected worldwide, the disorder’s profound impact on neurological development and quality of life has placed it at the forefront of pediatric neurology research. The increased visibility of rare diseases, bolstered by advocacy groups and digital awareness campaigns, has also pushed pharmaceutical companies and regulators to expedite research, treatment approvals, and compassionate use programs. Institutions in North America, Europe, and increasingly Asia-Pacific are establishing specialized epilepsy centers that focus on rare syndromes like Dravet, facilitating comprehensive care involving neurologists, geneticists, and developmental specialists. This global momentum is reshaping the research funding landscape and catalyzing collaborative, multi-stakeholder approaches toward more effective management.

How Are Advances in Therapeutics Transforming the Treatment Landscape?

The treatment landscape for Dravet Syndrome has evolved significantly in recent years, moving beyond conventional anti-epileptic drugs (AEDs) to include targeted and novel therapeutics. While traditional AEDs like valproate and clobazam remain foundational, they often provide limited seizure control, prompting a surge of innovation in more specialized drug development. FDA-approved therapies such as cannabidiol (CBD)-based Epidiolex and fenfluramine (Fintepla) have shown marked improvements in reducing seizure frequency and severity in Dravet patients. Moreover, investigational therapies targeting sodium channel dysfunction-the underlying cause of most Dravet cases-are in various stages of clinical trials. Antisense oligonucleotides (ASOs), gene therapy approaches, and RNA-targeting drugs are emerging as promising candidates that offer the possibility of disease modification rather than symptomatic relief. These treatments are increasingly being paired with digital monitoring tools and pharmacogenetic testing to tailor regimens to individual patients. The therapeutic evolution is not only improving clinical outcomes but also enhancing patient safety, reducing caregiver burden, and opening doors to longer-term neurodevelopmental gains.

Why Are Patient Advocacy and Regulatory Incentives Accelerating Innovation?

The growing influence of patient advocacy groups and the expanding ecosystem of rare disease funding are major accelerants in the Dravet Syndrome market. Organizations like the Dravet Syndrome Foundation and European counterparts have played a crucial role in connecting families, clinicians, and researchers to drive awareness, education, and collaborative research. Their efforts have translated into increased participation in clinical trials and real-world data collection, both of which are essential for refining treatment protocols. On the regulatory front, agencies such as the FDA, EMA, and PMDA have introduced rare pediatric disease and orphan drug designations that grant market exclusivity, tax incentives, and fast-track approvals to developers of Dravet-related therapies. These incentives significantly lower the barriers to entry for biotech firms and ensure that even small-scale trials receive the attention needed to translate promising science into available treatments. Pharmaceutical companies are also recognizing the commercial viability of orphan drugs, leading to increased licensing deals, R&D investments, and portfolio expansions in the neurodevelopmental disorder segment.

The Growth in the Dravet Syndrome Market Is Driven by Several Factors…

The growth in the Dravet Syndrome market is driven by several factors related to technological breakthroughs, evolving end-user needs, and shifting policy frameworks. Advances in genetic testing and next-generation sequencing have vastly improved diagnostic rates, allowing for earlier intervention and the possibility of precision medicine. On the treatment front, the emergence of novel drugs-especially those with FDA and EMA approvals-has transformed clinical pathways and expanded therapeutic options. From an end-use perspective, pediatric neurology centers, rare disease clinics, and integrated care models are adopting multidisciplinary approaches that create steady demand for specialized diagnostics and drugs. Consumer behavior, particularly among informed and proactive caregivers, is pushing for more tailored and cutting-edge treatment regimens, reinforcing the demand for innovation. Additionally, supportive government policies, rare disease registries, and public-private research collaborations are creating fertile ground for ongoing drug development and market expansion. Together, these dynamics are converting what was once a highly underserved condition into a rapidly evolving niche market with significant unmet needs and long-term growth potential.

SCOPE OF STUDY:

The report analyzes the Dravet Syndrome market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Seizure Type (Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures, Other Seizure Types); Diagnosis Type (Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis, SCN1A Testing Diagnosis); Treatment Type (Medication Treatment, Ketogenic Diet Treatment, Vagus Nerve Stimulation Treatment); End-Use (Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

• Anavex Life Sciences Corp.
• Aquestive Therapeutics, Inc.
• Biocodex S.A.
• Biscayne Neurotherapeutics, Inc.
• Eisai Co., Ltd.
• Encoded Therapeutics
• Epygenix Therapeutics, Inc.
• GW Pharmaceuticals plc
• INSYS Therapeutics, Inc.
• Marinus Pharmaceuticals, Inc.
• Neurocrine Biosciences, Inc.
• OPKO Health Inc.
• Otsuka Holdings Co., Ltd.
• Ovid Therapeutics Inc.
• PTC Therapeutics, Inc.
• Sage Therapeutics, Inc.
• Stoke Therapeutics, Inc.
• Supernus Pharmaceuticals, Inc.
• Takeda Pharmaceutical Company Ltd.
• Xenon Pharmaceuticals Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Dravet Syndrome - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Disease Awareness and Diagnosis Rates Spur Growth in Therapeutic Demand
  • Accelerated FDA and EMA Approvals Strengthen Business Case for Orphan Drugs
  • Advances in Genetic Screening Expand Market for Early Intervention Treatments
  • Rare Disease Incentive Programs Propel R&D Investment in Dravet Syndrome
  • Emergence of Gene and Cell Therapies Expands Pipeline of Transformative Treatment Options
  • Off-Label Drug Use and Repurposing Drive Interim Treatment Adoption
  • Increased Funding from Rare Disease Advocacy Groups Generates Momentum in Drug Discovery
  • Rising Pediatric Neurology Infrastructure in Developing Markets Expands Global Treatment Reach
  • Demand for Precision Medicine and Tailored Therapies Drives Innovation in Drug Delivery
  • Integration of AI in Genomic Analytics Strengthens Case for Personalized Treatment Protocols
  • Growing Focus on Quality of Life Metrics Accelerates Demand for Supportive Care Products
  • Market Entry of Biosimilars and Generics Poses Pricing Pressure on Innovator Therapies
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Dravet Syndrome Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Dravet Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Dravet Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Dravet Syndrome by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Myoclonic Seizures by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Myoclonic Seizures by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for Myoclonic Seizures by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Atonic Seizures by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Atonic Seizures by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for Atonic Seizures by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Partial Seizures by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Partial Seizures by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for Partial Seizures by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Tonic-Clonic Seizures by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Tonic-Clonic Seizures by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for Tonic-Clonic Seizures by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Photosensitive Seizures by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Photosensitive Seizures by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Photosensitive Seizures by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Other Seizure Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Other Seizure Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for Other Seizure Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Medication Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Medication Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 25: World 16-Year Perspective for Medication Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Ketogenic Diet Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Ketogenic Diet Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 28: World 16-Year Perspective for Ketogenic Diet Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Vagus Nerve Stimulation Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Vagus Nerve Stimulation Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 31: World 16-Year Perspective for Vagus Nerve Stimulation Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Pharma Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Pharma Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 34: World 16-Year Perspective for Pharma Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 37: World 16-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Diagnostic Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Diagnostic Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 40: World 16-Year Perspective for Diagnostic Laboratories End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 43: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Magnetic Resonance Imaging Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Magnetic Resonance Imaging Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 46: World 16-Year Perspective for Magnetic Resonance Imaging Diagnosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 47: World Recent Past, Current & Future Analysis for Electrocardiogram Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 48: World Historic Review for Electrocardiogram Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 49: World 16-Year Perspective for Electrocardiogram Diagnosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 50: World Recent Past, Current & Future Analysis for SCN1A Testing Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 51: World Historic Review for SCN1A Testing Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 52: World 16-Year Perspective for SCN1A Testing Diagnosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Dravet Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 53: USA Recent Past, Current & Future Analysis for Dravet Syndrome by Seizure Type - Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 54: USA Historic Review for Dravet Syndrome by Seizure Type - Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 55: USA 16-Year Perspective for Dravet Syndrome by Seizure Type - Percentage Breakdown of Value Sales for Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types for the Years 2014, 2025 & 2030
  • TABLE 56: USA Recent Past, Current & Future Analysis for Dravet Syndrome by Treatment Type - Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: USA Historic Review for Dravet Syndrome by Treatment Type - Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 58: USA 16-Year Perspective for Dravet Syndrome by Treatment Type - Percentage Breakdown of Value Sales for Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment for the Years 2014, 2025 & 2030
  • TABLE 59: USA Recent Past, Current & Future Analysis for Dravet Syndrome by End-Use - Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: USA Historic Review for Dravet Syndrome by End-Use - Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 61: USA 16-Year Perspective for Dravet Syndrome by End-Use - Percentage Breakdown of Value Sales for Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 62: USA Recent Past, Current & Future Analysis for Dravet Syndrome by Diagnosis Type - Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: USA Historic Review for Dravet Syndrome by Diagnosis Type - Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 64: USA 16-Year Perspective for Dravet Syndrome by Diagnosis Type - Percentage Breakdown of Value Sales for Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis for the Years 2014, 2025 & 2030
• CANADA
  • TABLE 65: Canada Recent Past, Current & Future Analysis for Dravet Syndrome by Seizure Type - Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Canada Historic Review for Dravet Syndrome by Seizure Type - Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 67: Canada 16-Year Perspective for Dravet Syndrome by Seizure Type - Percentage Breakdown of Value Sales for Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types for the Years 2014, 2025 & 2030
  • TABLE 68: Canada Recent Past, Current & Future Analysis for Dravet Syndrome by Treatment Type - Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Canada Historic Review for Dravet Syndrome by Treatment Type - Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 70: Canada 16-Year Perspective for Dravet Syndrome by Treatment Type - Percentage Breakdown of Value Sales for Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment for the Years 2014, 2025 & 2030
  • TABLE 71: Canada Recent Past, Current & Future Analysis for Dravet Syndrome by End-Use - Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Canada Historic Review for Dravet Syndrome by End-Use - Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 73: Canada 16-Year Perspective for Dravet Syndrome by End-Use - Percentage Breakdown of Value Sales for Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 74: Canada Recent Past, Current & Future Analysis for Dravet Syndrome by Diagnosis Type - Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Canada Historic Review for Dravet Syndrome by Diagnosis Type - Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 76: Canada 16-Year Perspective for Dravet Syndrome by Diagnosis Type - Percentage Breakdown of Value Sales for Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis for the Years 2014, 2025 & 2030
• JAPAN
  • Dravet Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 77: Japan Recent Past, Current & Future Analysis for Dravet Syndrome by Seizure Type - Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Japan Historic Review for Dravet Syndrome by Seizure Type - Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 79: Japan 16-Year Perspective for Dravet Syndrome by Seizure Type - Percentage Breakdown of Value Sales for Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types for the Years 2014, 2025 & 2030
  • TABLE 80: Japan Recent Past, Current & Future Analysis for Dravet Syndrome by Treatment Type - Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Japan Historic Review for Dravet Syndrome by Treatment Type - Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 82: Japan 16-Year Perspective for Dravet Syndrome by Treatment Type - Percentage Breakdown of Value Sales for Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment for the Years 2014, 2025 & 2030
  • TABLE 83: Japan Recent Past, Current & Future Analysis for Dravet Syndrome by End-Use - Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Japan Historic Review for Dravet Syndrome by End-Use - Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 85: Japan 16-Year Perspective for Dravet Syndrome by End-Use - Percentage Breakdown of Value Sales for Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 86: Japan Recent Past, Current & Future Analysis for Dravet Syndrome by Diagnosis Type - Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Japan Historic Review for Dravet Syndrome by Diagnosis Type - Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 88: Japan 16-Year Perspective for Dravet Syndrome by Diagnosis Type - Percentage Breakdown of Value Sales for Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis for the Years 2014, 2025 & 2030
• CHINA
  • Dravet Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 89: China Recent Past, Current & Future Analysis for Dravet Syndrome by Seizure Type - Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: China Historic Review for Dravet Syndrome by Seizure Type - Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 91: China 16-Year Perspective for Dravet Syndrome by Seizure Type - Percentage Breakdown of Value Sales for Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types for the Years 2014, 2025 & 2030
  • TABLE 92: China Recent Past, Current & Future Analysis for Dravet Syndrome by Treatment Type - Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: China Historic Review for Dravet Syndrome by Treatment Type - Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 94: China 16-Year Perspective for Dravet Syndrome by Treatment Type - Percentage Breakdown of Value Sales for Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment for the Years 2014, 2025 & 2030
  • TABLE 95: China Recent Past, Current & Future Analysis for Dravet Syndrome by End-Use - Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: China Historic Review for Dravet Syndrome by End-Use - Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 97: China 16-Year Perspective for Dravet Syndrome by End-Use - Percentage Breakdown of Value Sales for Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 98: China Recent Past, Current & Future Analysis for Dravet Syndrome by Diagnosis Type - Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: China Historic Review for Dravet Syndrome by Diagnosis Type - Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 100: China 16-Year Perspective for Dravet Syndrome by Diagnosis Type - Percentage Breakdown of Value Sales for Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis for the Years 2014, 2025 & 2030
• EUROPE
  • Dravet Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 101: Europe Recent Past, Current & Future Analysis for Dravet Syndrome by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 102: Europe Historic Review for Dravet Syndrome by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 103: Europe 16-Year Perspective for Dravet Syndrome by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
  • TABLE 104: Europe Recent Past, Current & Future Analysis for Dravet Syndrome by Seizure Type - Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Europe Historic Review for Dravet Syndrome by Seizure Type - Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 106: Europe 16-Year Perspective for Dravet Syndrome by Seizure Type - Percentage Breakdown of Value Sales for Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types for the Years 2014, 2025 & 2030
  • TABLE 107: Europe Recent Past, Current & Future Analysis for Dravet Syndrome by Treatment Type - Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Europe Historic Review for Dravet Syndrome by Treatment Type - Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 109: Europe 16-Year Perspective for Dravet Syndrome by Treatment Type - Percentage Breakdown of Value Sales for Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment for the Years 2014, 2025 & 2030
  • TABLE 110: Europe Recent Past, Current & Future Analysis for Dravet Syndrome by End-Use - Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Europe Historic Review for Dravet Syndrome by End-Use - Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 112: Europe 16-Year Perspective for Dravet Syndrome by End-Use - Percentage Breakdown of Value Sales for Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 113: Europe Recent Past, Current & Future Analysis for Dravet Syndrome by Diagnosis Type - Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Europe Historic Review for Dravet Syndrome by Diagnosis Type - Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 115: Europe 16-Year Perspective for Dravet Syndrome by Diagnosis Type - Percentage Breakdown of Value Sales for Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis for the Years 2014, 2025 & 2030
• FRANCE
  • Dravet Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 116: France Recent Past, Current & Future Analysis for Dravet Syndrome by Seizure Type - Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: France Historic Review for Dravet Syndrome by Seizure Type - Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 118: France 16-Year Perspective for Dravet Syndrome by Seizure Type - Percentage Breakdown of Value Sales for Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types for the Years 2014, 2025 & 2030
  • TABLE 119: France Recent Past, Current & Future Analysis for Dravet Syndrome by Treatment Type - Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: France Historic Review for Dravet Syndrome by Treatment Type - Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 121: France 16-Year Perspective for Dravet Syndrome by Treatment Type - Percentage Breakdown of Value Sales for Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment for the Years 2014, 2025 & 2030
  • TABLE 122: France Recent Past, Current & Future Analysis for Dravet Syndrome by End-Use - Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: France Historic Review for Dravet Syndrome by End-Use - Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 124: France 16-Year Perspective for Dravet Syndrome by End-Use - Percentage Breakdown of Value Sales for Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 125: France Recent Past, Current & Future Analysis for Dravet Syndrome by Diagnosis Type - Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: France Historic Review for Dravet Syndrome by Diagnosis Type - Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 127: France 16-Year Perspective for Dravet Syndrome by Diagnosis Type - Percentage Breakdown of Value Sales for Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis for the Years 2014, 2025 & 2030
• GERMANY
  • Dravet Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 128: Germany Recent Past, Current & Future Analysis for Dravet Syndrome by Seizure Type - Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Germany Historic Review for Dravet Syndrome by Seizure Type - Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 130: Germany 16-Year Perspective for Dravet Syndrome by Seizure Type - Percentage Breakdown of Value Sales for Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types for the Years 2014, 2025 & 2030
  • TABLE 131: Germany Recent Past, Current & Future Analysis for Dravet Syndrome by Treatment Type - Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Germany Historic Review for Dravet Syndrome by Treatment Type - Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 133: Germany 16-Year Perspective for Dravet Syndrome by Treatment Type - Percentage Breakdown of Value Sales for Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment for the Years 2014, 2025 & 2030
  • TABLE 134: Germany Recent Past, Current & Future Analysis for Dravet Syndrome by End-Use - Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Germany Historic Review for Dravet Syndrome by End-Use - Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 136: Germany 16-Year Perspective for Dravet Syndrome by End-Use - Percentage Breakdown of Value Sales for Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 137: Germany Recent Past, Current & Future Analysis for Dravet Syndrome by Diagnosis Type - Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Germany Historic Review for Dravet Syndrome by Diagnosis Type - Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 139: Germany 16-Year Perspective for Dravet Syndrome by Diagnosis Type - Percentage Breakdown of Value Sales for Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis for the Years 2014, 2025 & 2030
• ITALY
  • TABLE 140: Italy Recent Past, Current & Future Analysis for Dravet Syndrome by Seizure Type - Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Italy Historic Review for Dravet Syndrome by Seizure Type - Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 142: Italy 16-Year Perspective for Dravet Syndrome by Seizure Type - Percentage Breakdown of Value Sales for Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types for the Years 2014, 2025 & 2030
  • TABLE 143: Italy Recent Past, Current & Future Analysis for Dravet Syndrome by Treatment Type - Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Italy Historic Review for Dravet Syndrome by Treatment Type - Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 145: Italy 16-Year Perspective for Dravet Syndrome by Treatment Type - Percentage Breakdown of Value Sales for Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment for the Years 2014, 2025 & 2030
  • TABLE 146: Italy Recent Past, Current & Future Analysis for Dravet Syndrome by End-Use - Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Italy Historic Review for Dravet Syndrome by End-Use - Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 148: Italy 16-Year Perspective for Dravet Syndrome by End-Use - Percentage Breakdown of Value Sales for Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 149: Italy Recent Past, Current & Future Analysis for Dravet Syndrome by Diagnosis Type - Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Italy Historic Review for Dravet Syndrome by Diagnosis Type - Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 151: Italy 16-Year Perspective for Dravet Syndrome by Diagnosis Type - Percentage Breakdown of Value Sales for Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis for the Years 2014, 2025 & 2030
• UNITED KINGDOM
  • Dravet Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 152: UK Recent Past, Current & Future Analysis for Dravet Syndrome by Seizure Type - Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: UK Historic Review for Dravet Syndrome by Seizure Type - Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 154: UK 16-Year Perspective for Dravet Syndrome by Seizure Type - Percentage Breakdown of Value Sales for Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types for the Years 2014, 2025 & 2030
  • TABLE 155: UK Recent Past, Current & Future Analysis for Dravet Syndrome by Treatment Type - Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: UK Historic Review for Dravet Syndrome by Treatment Type - Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 157: UK 16-Year Perspective for Dravet Syndrome by Treatment Type - Percentage Breakdown of Value Sales for Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment for the Years 2014, 2025 & 2030
  • TABLE 158: UK Recent Past, Current & Future Analysis for Dravet Syndrome by End-Use - Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: UK Historic Review for Dravet Syndrome by End-Use - Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 160: UK 16-Year Perspective for Dravet Syndrome by End-Use - Percentage Breakdown of Value Sales for Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 161: UK Recent Past, Current & Future Analysis for Dravet Syndrome by Diagnosis Type - Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: UK Historic Review for Dravet Syndrome by Diagnosis Type - Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 163: UK 16-Year Perspective for Dravet Syndrome by Diagnosis Type - Percentage Breakdown of Value Sales for Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis for the Years 2014, 2025 & 2030
• SPAIN
  • TABLE 164: Spain Recent Past, Current & Future Analysis for Dravet Syndrome by Seizure Type - Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Spain Historic Review for Dravet Syndrome by Seizure Type - Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 166: Spain 16-Year Perspective for Dravet Syndrome by Seizure Type - Percentage Breakdown of Value Sales for Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types for the Years 2014, 2025 & 2030
  • TABLE 167: Spain Recent Past, Current & Future Analysis for Dravet Syndrome by Treatment Type - Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Spain Historic Review for Dravet Syndrome by Treatment Type - Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 169: Spain 16-Year Perspective for Dravet Syndrome by Treatment Type - Percentage Breakdown of Value Sales for Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment for the Years 2014, 2025 & 2030
  • TABLE 170: Spain Recent Past, Current & Future Analysis for Dravet Syndrome by End-Use - Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Spain Historic Review for Dravet Syndrome by End-Use - Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 172: Spain 16-Year Perspective for Dravet Syndrome by End-Use - Percentage Breakdown of Value Sales for Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 173: Spain Recent Past, Current & Future Analysis for Dravet Syndrome by Diagnosis Type - Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Spain Historic Review for Dravet Syndrome by Diagnosis Type - Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 175: Spain 16-Year Perspective for Dravet Syndrome by Diagnosis Type - Percentage Breakdown of Value Sales for Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis for the Years 2014, 2025 & 2030
• RUSSIA
  • TABLE 176: Russia Recent Past, Current & Future Analysis for Dravet Syndrome by Seizure Type - Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Russia Historic Review for Dravet Syndrome by Seizure Type - Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 178: Russia 16-Year Perspective for Dravet Syndrome by Seizure Type - Percentage Breakdown of Value Sales for Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types for the Years 2014, 2025 & 2030
  • TABLE 179: Russia Recent Past, Current & Future Analysis for Dravet Syndrome by Treatment Type - Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Russia Historic Review for Dravet Syndrome by Treatment Type - Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 181: Russia 16-Year Perspective for Dravet Syndrome by Treatment Type - Percentage Breakdown of Value Sales for Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment for the Years 2014, 2025 & 2030
  • TABLE 182: Russia Recent Past, Current & Future Analysis for Dravet Syndrome by End-Use - Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Russia Historic Review for Dravet Syndrome by End-Use - Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 184: Russia 16-Year Perspective for Dravet Syndrome by End-Use - Percentage Breakdown of Value Sales for Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 185: Russia Recent Past, Current & Future Analysis for Dravet Syndrome by Diagnosis Type - Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Russia Historic Review for Dravet Syndrome by Diagnosis Type - Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 187: Russia 16-Year Perspective for Dravet Syndrome by Diagnosis Type - Percentage Breakdown of Value Sales for Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis for the Years 2014, 2025 & 2030
• REST OF EUROPE
  • TABLE 188: Rest of Europe Recent Past, Current & Future Analysis for Dravet Syndrome by Seizure Type - Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Europe Historic Review for Dravet Syndrome by Seizure Type - Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 190: Rest of Europe 16-Year Perspective for Dravet Syndrome by Seizure Type - Percentage Breakdown of Value Sales for Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types for the Years 2014, 2025 & 2030
  • TABLE 191: Rest of Europe Recent Past, Current & Future Analysis for Dravet Syndrome by Treatment Type - Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Europe Historic Review for Dravet Syndrome by Treatment Type - Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 193: Rest of Europe 16-Year Perspective for Dravet Syndrome by Treatment Type - Percentage Breakdown of Value Sales for Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment for the Years 2014, 2025 & 2030
  • TABLE 194: Rest of Europe Recent Past, Current & Future Analysis for Dravet Syndrome by End-Use - Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Europe Historic Review for Dravet Syndrome by End-Use - Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 196: Rest of Europe 16-Year Perspective for Dravet Syndrome by End-Use - Percentage Breakdown of Value Sales for Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 197: Rest of Europe Recent Past, Current & Future Analysis for Dravet Syndrome by Diagnosis Type - Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Rest of Europe Historic Review for Dravet Syndrome by Diagnosis Type - Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 199: Rest of Europe 16-Year Perspective for Dravet Syndrome by Diagnosis Type - Percentage Breakdown of Value Sales for Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis for the Years 2014, 2025 & 2030
• ASIA-PACIFIC
  • Dravet Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for Dravet Syndrome by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 201: Asia-Pacific Historic Review for Dravet Syndrome by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 202: Asia-Pacific 16-Year Perspective for Dravet Syndrome by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
  • TABLE 203: Asia-Pacific Recent Past, Current & Future Analysis for Dravet Syndrome by Seizure Type - Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Asia-Pacific Historic Review for Dravet Syndrome by Seizure Type - Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 205: Asia-Pacific 16-Year Perspective for Dravet Syndrome by Seizure Type - Percentage Breakdown of Value Sales for Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types for the Years 2014, 2025 & 2030
  • TABLE 206: Asia-Pacific Recent Past, Current & Future Analysis for Dravet Syndrome by Treatment Type - Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Asia-Pacific Historic Review for Dravet Syndrome by Treatment Type - Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 208: Asia-Pacific 16-Year Perspective for Dravet Syndrome by Treatment Type - Percentage Breakdown of Value Sales for Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment for the Years 2014, 2025 & 2030
  • TABLE 209: Asia-Pacific Recent Past, Current & Future Analysis for Dravet Syndrome by End-Use - Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Asia-Pacific Historic Review for Dravet Syndrome by End-Use - Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 211: Asia-Pacific 16-Year Perspective for Dravet Syndrome by End-Use - Percentage Breakdown of Value Sales for Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 212: Asia-Pacific Recent Past, Current & Future Analysis for Dravet Syndrome by Diagnosis Type - Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Asia-Pacific Historic Review for Dravet Syndrome by Diagnosis Type - Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 214: Asia-Pacific 16-Year Perspective for Dravet Syndrome by Diagnosis Type - Percentage Breakdown of Value Sales for Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis for the Years 2014, 2025 & 2030
• AUSTRALIA
  • Dravet Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 215: Australia Recent Past, Current & Future Analysis for Dravet Syndrome by Seizure Type - Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Australia Historic Review for Dravet Syndrome by Seizure Type - Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 217: Australia 16-Year Perspective for Dravet Syndrome by Seizure Type - Percentage Breakdown of Value Sales for Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types for the Years 2014, 2025 & 2030
  • TABLE 218: Australia Recent Past, Current & Future Analysis for Dravet Syndrome by Treatment Type - Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Australia Historic Review for Dravet Syndrome by Treatment Type - Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 220: Australia 16-Year Perspective for Dravet Syndrome by Treatment Type - Percentage Breakdown of Value Sales for Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment for the Years 2014, 2025 & 2030
  • TABLE 221: Australia Recent Past, Current & Future Analysis for Dravet Syndrome by End-Use - Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Australia Historic Review for Dravet Syndrome by End-Use - Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 223: Australia 16-Year Perspective for Dravet Syndrome by End-Use - Percentage Breakdown of Value Sales for Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 224: Australia Recent Past, Current & Future Analysis for Dravet Syndrome by Diagnosis Type - Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Australia Historic Review for Dravet Syndrome by Diagnosis Type - Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 226: Australia 16-Year Perspective for Dravet Syndrome by Diagnosis Type - Percentage Breakdown of Value Sales for Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis for the Years 2014, 2025 & 2030
• INDIA
  • Dravet Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 227: India Recent Past, Current & Future Analysis for Dravet Syndrome by Seizure Type - Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 228: India Historic Review for Dravet Syndrome by Seizure Type - Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 229: India 16-Year Perspective for Dravet Syndrome by Seizure Type - Percentage Breakdown of Value Sales for Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types for the Years 2014, 2025 & 2030
  • TABLE 230: India Recent Past, Current & Future Analysis for Dravet Syndrome by Treatment Type - Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 231: India Historic Review for Dravet Syndrome by Treatment Type - Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 232: India 16-Year Perspective for Dravet Syndrome by Treatment Type - Percentage Breakdown of Value Sales for Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment for the Years 2014, 2025 & 2030
  • TABLE 233: India Recent Past, Current & Future Analysis for Dravet Syndrome by End-Use - Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 234: India Historic Review for Dravet Syndrome by End-Use - Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 235: India 16-Year Perspective for Dravet Syndrome by End-Use - Percentage Breakdown of Value Sales for Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 236: India Recent Past, Current & Future Analysis for Dravet Syndrome by Diagnosis Type - Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 237: India Historic Review for Dravet Syndrome by Diagnosis Type - Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 238: India 16-Year Perspective for Dravet Syndrome by Diagnosis Type - Percentage Breakdown of Value Sales for Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis for the Years 2014, 2025 & 2030
• SOUTH KOREA
  • TABLE 239: South Korea Recent Past, Current & Future Analysis for Dravet Syndrome by Seizure Type - Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 240: South Korea Historic Review for Dravet Syndrome by Seizure Type - Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 241: South Korea 16-Year Perspective for Dravet Syndrome by Seizure Type - Percentage Breakdown of Value Sales for Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types for the Years 2014, 2025 & 2030
  • TABLE 242: South Korea Recent Past, Current & Future Analysis for Dravet Syndrome by Treatment Type - Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 243: South Korea Historic Review for Dravet Syndrome by Treatment Type - Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 244: South Korea 16-Year Perspective for Dravet Syndrome by Treatment Type - Percentage Breakdown of Value Sales for Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment for the Years 2014, 2025 & 2030
  • TABLE 245: South Korea Recent Past, Current & Future Analysis for Dravet Syndrome by End-Use - Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 246: South Korea Historic Review for Dravet Syndrome by End-Use - Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 247: South Korea 16-Year Perspective for Dravet Syndrome by End-Use - Percentage Breakdown of Value Sales for Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 248: South Korea Recent Past, Current & Future Analysis for Dravet Syndrome by Diagnosis Type - Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 249: South Korea Historic Review for Dravet Syndrome by Diagnosis Type - Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 250: South Korea 16-Year Perspective for Dravet Syndrome by Diagnosis Type - Percentage Breakdown of Value Sales for Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis for the Years 2014, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 251: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Dravet Syndrome by Seizure Type - Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Rest of Asia-Pacific Historic Review for Dravet Syndrome by Seizure Type - Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 253: Rest of Asia-Pacific 16-Year Perspective for Dravet Syndrome by Seizure Type - Percentage Breakdown of Value Sales for Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types for the Years 2014, 2025 & 2030
  • TABLE 254: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Dravet Syndrome by Treatment Type - Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Rest of Asia-Pacific Historic Review for Dravet Syndrome by Treatment Type - Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 256: Rest of Asia-Pacific 16-Year Perspective for Dravet Syndrome by Treatment Type - Percentage Breakdown of Value Sales for Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment for the Years 2014, 2025 & 2030
  • TABLE 257: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Dravet Syndrome by End-Use - Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Rest of Asia-Pacific Historic Review for Dravet Syndrome by End-Use - Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 259: Rest of Asia-Pacific 16-Year Perspective for Dravet Syndrome by End-Use - Percentage Breakdown of Value Sales for Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 260: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Dravet Syndrome by Diagnosis Type - Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Rest of Asia-Pacific Historic Review for Dravet Syndrome by Diagnosis Type - Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 262: Rest of Asia-Pacific 16-Year Perspective for Dravet Syndrome by Diagnosis Type - Percentage Breakdown of Value Sales for Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis for the Years 2014, 2025 & 2030
• LATIN AMERICA
  • Dravet Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 263: Latin America Recent Past, Current & Future Analysis for Dravet Syndrome by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 264: Latin America Historic Review for Dravet Syndrome by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 265: Latin America 16-Year Perspective for Dravet Syndrome by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
  • TABLE 266: Latin America Recent Past, Current & Future Analysis for Dravet Syndrome by Seizure Type - Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Latin America Historic Review for Dravet Syndrome by Seizure Type - Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 268: Latin America 16-Year Perspective for Dravet Syndrome by Seizure Type - Percentage Breakdown of Value Sales for Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types for the Years 2014, 2025 & 2030
  • TABLE 269: Latin America Recent Past, Current & Future Analysis for Dravet Syndrome by Treatment Type - Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Latin America Historic Review for Dravet Syndrome by Treatment Type - Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 271: Latin America 16-Year Perspective for Dravet Syndrome by Treatment Type - Percentage Breakdown of Value Sales for Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment for the Years 2014, 2025 & 2030
  • TABLE 272: Latin America Recent Past, Current & Future Analysis for Dravet Syndrome by End-Use - Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Latin America Historic Review for Dravet Syndrome by End-Use - Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 274: Latin America 16-Year Perspective for Dravet Syndrome by End-Use - Percentage Breakdown of Value Sales for Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 275: Latin America Recent Past, Current & Future Analysis for Dravet Syndrome by Diagnosis Type - Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Latin America Historic Review for Dravet Syndrome by Diagnosis Type - Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 277: Latin America 16-Year Perspective for Dravet Syndrome by Diagnosis Type - Percentage Breakdown of Value Sales for Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis for the Years 2014, 2025 & 2030
• ARGENTINA
  • TABLE 278: Argentina Recent Past, Current & Future Analysis for Dravet Syndrome by Seizure Type - Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Argentina Historic Review for Dravet Syndrome by Seizure Type - Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 280: Argentina 16-Year Perspective for Dravet Syndrome by Seizure Type - Percentage Breakdown of Value Sales for Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types for the Years 2014, 2025 & 2030
  • TABLE 281: Argentina Recent Past, Current & Future Analysis for Dravet Syndrome by Treatment Type - Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Argentina Historic Review for Dravet Syndrome by Treatment Type - Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 283: Argentina 16-Year Perspective for Dravet Syndrome by Treatment Type - Percentage Breakdown of Value Sales for Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment for the Years 2014, 2025 & 2030
  • TABLE 284: Argentina Recent Past, Current & Future Analysis for Dravet Syndrome by End-Use - Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Argentina Historic Review for Dravet Syndrome by End-Use - Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 286: Argentina 16-Year Perspective for Dravet Syndrome by End-Use - Percentage Breakdown of Value Sales for Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 287: Argentina Recent Past, Current & Future Analysis for Dravet Syndrome by Diagnosis Type - Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Argentina Historic Review for Dravet Syndrome by Diagnosis Type - Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 289: Argentina 16-Year Perspective for Dravet Syndrome by Diagnosis Type - Percentage Breakdown of Value Sales for Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis for the Years 2014, 2025 & 2030
• BRAZIL
  • TABLE 290: Brazil Recent Past, Current & Future Analysis for Dravet Syndrome by Seizure Type - Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Brazil Historic Review for Dravet Syndrome by Seizure Type - Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 292: Brazil 16-Year Perspective for Dravet Syndrome by Seizure Type - Percentage Breakdown of Value Sales for Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types for the Years 2014, 2025 & 2030
  • TABLE 293: Brazil Recent Past, Current & Future Analysis for Dravet Syndrome by Treatment Type - Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Brazil Historic Review for Dravet Syndrome by Treatment Type - Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 295: Brazil 16-Year Perspective for Dravet Syndrome by Treatment Type - Percentage Breakdown of Value Sales for Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment for the Years 2014, 2025 & 2030
  • TABLE 296: Brazil Recent Past, Current & Future Analysis for Dravet Syndrome by End-Use - Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Brazil Historic Review for Dravet Syndrome by End-Use - Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 298: Brazil 16-Year Perspective for Dravet Syndrome by End-Use - Percentage Breakdown of Value Sales for Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 299: Brazil Recent Past, Current & Future Analysis for Dravet Syndrome by Diagnosis Type - Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Brazil Historic Review for Dravet Syndrome by Diagnosis Type - Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 301: Brazil 16-Year Perspective for Dravet Syndrome by Diagnosis Type - Percentage Breakdown of Value Sales for Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis for the Years 2014, 2025 & 2030
• MEXICO
  • TABLE 302: Mexico Recent Past, Current & Future Analysis for Dravet Syndrome by Seizure Type - Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Mexico Historic Review for Dravet Syndrome by Seizure Type - Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 304: Mexico 16-Year Perspective for Dravet Syndrome by Seizure Type - Percentage Breakdown of Value Sales for Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types for the Years 2014, 2025 & 2030
  • TABLE 305: Mexico Recent Past, Current & Future Analysis for Dravet Syndrome by Treatment Type - Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Mexico Historic Review for Dravet Syndrome by Treatment Type - Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 307: Mexico 16-Year Perspective for Dravet Syndrome by Treatment Type - Percentage Breakdown of Value Sales for Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment for the Years 2014, 2025 & 2030
  • TABLE 308: Mexico Recent Past, Current & Future Analysis for Dravet Syndrome by End-Use - Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Mexico Historic Review for Dravet Syndrome by End-Use - Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 310: Mexico 16-Year Perspective for Dravet Syndrome by End-Use - Percentage Breakdown of Value Sales for Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 311: Mexico Recent Past, Current & Future Analysis for Dravet Syndrome by Diagnosis Type - Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Mexico Historic Review for Dravet Syndrome by Diagnosis Type - Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 313: Mexico 16-Year Perspective for Dravet Syndrome by Diagnosis Type - Percentage Breakdown of Value Sales for Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis for the Years 2014, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 314: Rest of Latin America Recent Past, Current & Future Analysis for Dravet Syndrome by Seizure Type - Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Rest of Latin America Historic Review for Dravet Syndrome by Seizure Type - Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 316: Rest of Latin America 16-Year Perspective for Dravet Syndrome by Seizure Type - Percentage Breakdown of Value Sales for Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types for the Years 2014, 2025 & 2030
  • TABLE 317: Rest of Latin America Recent Past, Current & Future Analysis for Dravet Syndrome by Treatment Type - Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Rest of Latin America Historic Review for Dravet Syndrome by Treatment Type - Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 319: Rest of Latin America 16-Year Perspective for Dravet Syndrome by Treatment Type - Percentage Breakdown of Value Sales for Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment for the Years 2014, 2025 & 2030
  • TABLE 320: Rest of Latin America Recent Past, Current & Future Analysis for Dravet Syndrome by End-Use - Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Rest of Latin America Historic Review for Dravet Syndrome by End-Use - Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 322: Rest of Latin America 16-Year Perspective for Dravet Syndrome by End-Use - Percentage Breakdown of Value Sales for Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 323: Rest of Latin America Recent Past, Current & Future Analysis for Dravet Syndrome by Diagnosis Type - Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 324: Rest of Latin America Historic Review for Dravet Syndrome by Diagnosis Type - Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 325: Rest of Latin America 16-Year Perspective for Dravet Syndrome by Diagnosis Type - Percentage Breakdown of Value Sales for Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis for the Years 2014, 2025 & 2030
• MIDDLE EAST
  • Dravet Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 326: Middle East Recent Past, Current & Future Analysis for Dravet Syndrome by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 327: Middle East Historic Review for Dravet Syndrome by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 328: Middle East 16-Year Perspective for Dravet Syndrome by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
  • TABLE 329: Middle East Recent Past, Current & Future Analysis for Dravet Syndrome by Seizure Type - Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 330: Middle East Historic Review for Dravet Syndrome by Seizure Type - Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 331: Middle East 16-Year Perspective for Dravet Syndrome by Seizure Type - Percentage Breakdown of Value Sales for Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types for the Years 2014, 2025 & 2030
  • TABLE 332: Middle East Recent Past, Current & Future Analysis for Dravet Syndrome by Treatment Type - Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 333: Middle East Historic Review for Dravet Syndrome by Treatment Type - Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 334: Middle East 16-Year Perspective for Dravet Syndrome by Treatment Type - Percentage Breakdown of Value Sales for Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment for the Years 2014, 2025 & 2030
  • TABLE 335: Middle East Recent Past, Current & Future Analysis for Dravet Syndrome by End-Use - Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 336: Middle East Historic Review for Dravet Syndrome by End-Use - Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 337: Middle East 16-Year Perspective for Dravet Syndrome by End-Use - Percentage Breakdown of Value Sales for Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 338: Middle East Recent Past, Current & Future Analysis for Dravet Syndrome by Diagnosis Type - Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 339: Middle East Historic Review for Dravet Syndrome by Diagnosis Type - Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 340: Middle East 16-Year Perspective for Dravet Syndrome by Diagnosis Type - Percentage Breakdown of Value Sales for Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis for the Years 2014, 2025 & 2030
• IRAN
  • TABLE 341: Iran Recent Past, Current & Future Analysis for Dravet Syndrome by Seizure Type - Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 342: Iran Historic Review for Dravet Syndrome by Seizure Type - Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 343: Iran 16-Year Perspective for Dravet Syndrome by Seizure Type - Percentage Breakdown of Value Sales for Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types for the Years 2014, 2025 & 2030
  • TABLE 344: Iran Recent Past, Current & Future Analysis for Dravet Syndrome by Treatment Type - Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 345: Iran Historic Review for Dravet Syndrome by Treatment Type - Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 346: Iran 16-Year Perspective for Dravet Syndrome by Treatment Type - Percentage Breakdown of Value Sales for Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment for the Years 2014, 2025 & 2030
  • TABLE 347: Iran Recent Past, Current & Future Analysis for Dravet Syndrome by End-Use - Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 348: Iran Historic Review for Dravet Syndrome by End-Use - Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 349: Iran 16-Year Perspective for Dravet Syndrome by End-Use - Percentage Breakdown of Value Sales for Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 350: Iran Recent Past, Current & Future Analysis for Dravet Syndrome by Diagnosis Type - Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 351: Iran Historic Review for Dravet Syndrome by Diagnosis Type - Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 352: Iran 16-Year Perspective for Dravet Syndrome by Diagnosis Type - Percentage Breakdown of Value Sales for Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis for the Years 2014, 2025 & 2030
• ISRAEL
  • TABLE 353: Israel Recent Past, Current & Future Analysis for Dravet Syndrome by Seizure Type - Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 354: Israel Historic Review for Dravet Syndrome by Seizure Type - Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 355: Israel 16-Year Perspective for Dravet Syndrome by Seizure Type - Percentage Breakdown of Value Sales for Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types for the Years 2014, 2025 & 2030
  • TABLE 356: Israel Recent Past, Current & Future Analysis for Dravet Syndrome by Treatment Type - Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 357: Israel Historic Review for Dravet Syndrome by Treatment Type - Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 358: Israel 16-Year Perspective for Dravet Syndrome by Treatment Type - Percentage Breakdown of Value Sales for Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment for the Years 2014, 2025 & 2030
  • TABLE 359: Israel Recent Past, Current & Future Analysis for Dravet Syndrome by End-Use - Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 360: Israel Historic Review for Dravet Syndrome by End-Use - Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 361: Israel 16-Year Perspective for Dravet Syndrome by End-Use - Percentage Breakdown of Value Sales for Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 362: Israel Recent Past, Current & Future Analysis for Dravet Syndrome by Diagnosis Type - Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 363: Israel Historic Review for Dravet Syndrome by Diagnosis Type - Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 364: Israel 16-Year Perspective for Dravet Syndrome by Diagnosis Type - Percentage Breakdown of Value Sales for Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis for the Years 2014, 2025 & 2030
• SAUDI ARABIA
  • TABLE 365: Saudi Arabia Recent Past, Current & Future Analysis for Dravet Syndrome by Seizure Type - Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 366: Saudi Arabia Historic Review for Dravet Syndrome by Seizure Type - Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 367: Saudi Arabia 16-Year Perspective for Dravet Syndrome by Seizure Type - Percentage Breakdown of Value Sales for Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types for the Years 2014, 2025 & 2030
  • TABLE 368: Saudi Arabia Recent Past, Current & Future Analysis for Dravet Syndrome by Treatment Type - Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 369: Saudi Arabia Historic Review for Dravet Syndrome by Treatment Type - Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 370: Saudi Arabia 16-Year Perspective for Dravet Syndrome by Treatment Type - Percentage Breakdown of Value Sales for Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment for the Years 2014, 2025 & 2030
  • TABLE 371: Saudi Arabia Recent Past, Current & Future Analysis for Dravet Syndrome by End-Use - Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 372: Saudi Arabia Historic Review for Dravet Syndrome by End-Use - Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 373: Saudi Arabia 16-Year Perspective for Dravet Syndrome by End-Use - Percentage Breakdown of Value Sales for Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 374: Saudi Arabia Recent Past, Current & Future Analysis for Dravet Syndrome by Diagnosis Type - Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 375: Saudi Arabia Historic Review for Dravet Syndrome by Diagnosis Type - Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 376: Saudi Arabia 16-Year Perspective for Dravet Syndrome by Diagnosis Type - Percentage Breakdown of Value Sales for Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis for the Years 2014, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 377: UAE Recent Past, Current & Future Analysis for Dravet Syndrome by Seizure Type - Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 378: UAE Historic Review for Dravet Syndrome by Seizure Type - Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 379: UAE 16-Year Perspective for Dravet Syndrome by Seizure Type - Percentage Breakdown of Value Sales for Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types for the Years 2014, 2025 & 2030
  • TABLE 380: UAE Recent Past, Current & Future Analysis for Dravet Syndrome by Treatment Type - Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 381: UAE Historic Review for Dravet Syndrome by Treatment Type - Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 382: UAE 16-Year Perspective for Dravet Syndrome by Treatment Type - Percentage Breakdown of Value Sales for Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment for the Years 2014, 2025 & 2030
  • TABLE 383: UAE Recent Past, Current & Future Analysis for Dravet Syndrome by End-Use - Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 384: UAE Historic Review for Dravet Syndrome by End-Use - Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 385: UAE 16-Year Perspective for Dravet Syndrome by End-Use - Percentage Breakdown of Value Sales for Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 386: UAE Recent Past, Current & Future Analysis for Dravet Syndrome by Diagnosis Type - Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 387: UAE Historic Review for Dravet Syndrome by Diagnosis Type - Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 388: UAE 16-Year Perspective for Dravet Syndrome by Diagnosis Type - Percentage Breakdown of Value Sales for Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis for the Years 2014, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 389: Rest of Middle East Recent Past, Current & Future Analysis for Dravet Syndrome by Seizure Type - Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 390: Rest of Middle East Historic Review for Dravet Syndrome by Seizure Type - Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 391: Rest of Middle East 16-Year Perspective for Dravet Syndrome by Seizure Type - Percentage Breakdown of Value Sales for Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types for the Years 2014, 2025 & 2030
  • TABLE 392: Rest of Middle East Recent Past, Current & Future Analysis for Dravet Syndrome by Treatment Type - Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 393: Rest of Middle East Historic Review for Dravet Syndrome by Treatment Type - Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 394: Rest of Middle East 16-Year Perspective for Dravet Syndrome by Treatment Type - Percentage Breakdown of Value Sales for Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment for the Years 2014, 2025 & 2030
  • TABLE 395: Rest of Middle East Recent Past, Current & Future Analysis for Dravet Syndrome by End-Use - Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 396: Rest of Middle East Historic Review for Dravet Syndrome by End-Use - Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 397: Rest of Middle East 16-Year Perspective for Dravet Syndrome by End-Use - Percentage Breakdown of Value Sales for Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 398: Rest of Middle East Recent Past, Current & Future Analysis for Dravet Syndrome by Diagnosis Type - Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 399: Rest of Middle East Historic Review for Dravet Syndrome by Diagnosis Type - Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 400: Rest of Middle East 16-Year Perspective for Dravet Syndrome by Diagnosis Type - Percentage Breakdown of Value Sales for Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis for the Years 2014, 2025 & 2030
• AFRICA
  • Dravet Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 401: Africa Recent Past, Current & Future Analysis for Dravet Syndrome by Seizure Type - Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 402: Africa Historic Review for Dravet Syndrome by Seizure Type - Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 403: Africa 16-Year Perspective for Dravet Syndrome by Seizure Type - Percentage Breakdown of Value Sales for Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive Seizures and Other Seizure Types for the Years 2014, 2025 & 2030
  • TABLE 404: Africa Recent Past, Current & Future Analysis for Dravet Syndrome by Treatment Type - Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 405: Africa Historic Review for Dravet Syndrome by Treatment Type - Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 406: Africa 16-Year Perspective for Dravet Syndrome by Treatment Type - Percentage Breakdown of Value Sales for Medication Treatment, Ketogenic Diet Treatment and Vagus Nerve Stimulation Treatment for the Years 2014, 2025 & 2030
  • TABLE 407: Africa Recent Past, Current & Future Analysis for Dravet Syndrome by End-Use - Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 408: Africa Historic Review for Dravet Syndrome by End-Use - Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 409: Africa 16-Year Perspective for Dravet Syndrome by End-Use - Percentage Breakdown of Value Sales for Pharma Companies End-Use, Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 410: Africa Recent Past, Current & Future Analysis for Dravet Syndrome by Diagnosis Type - Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 411: Africa Historic Review for Dravet Syndrome by Diagnosis Type - Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 412: Africa 16-Year Perspective for Dravet Syndrome by Diagnosis Type - Percentage Breakdown of Value Sales for Magnetic Resonance Imaging Diagnosis, Electrocardiogram Diagnosis and SCN1A Testing Diagnosis for the Years 2014, 2025 & 2030

IV. COMPETITION